Anna Brouwer

2 41 Prolonged cone b-wave is associated with severity of inflammation Results Patient characteristics Table 1 shows an overview of patient characteristics of both group A and B. The median age at ERG performance was, as expected, higher in group B compared to group A (54.9 years of age vs 48.4 years of age respectively, P = .007). In both groups there were more females than males. In group B, both eyes were more frequently affected than those in group A. However, analysis of only patients with a bilateral uveitis yielded no different results. Also, patients in group B were more frequently treated with disease-modifying antirheumatic drugs and had more frequently glaucoma. No differences were observed between groups based on diagnosis or anatomical localization of uveitis. Group A (n=80) Group B (n=120) P-value Age, a median [IQR] 48.36 [31.41, 59.38] 54.91 [41.99, 66.62] 0.007 Male gender, N (%) 29 (36.2) 32 (26.7) 0.199 Bilateral uveitis, a N (%) 47 (58.8) 112 (93.3) <0.001 Localization, N (%) 0.446 Anterior 5 (6.2) 15 (12.5) Intermediate 9 (11.2) 16 (13.3) Posterior 40 (50.0) 57 (47.5) Panuveitis 26 (32.5) 32 (26.7) Diagnosis, N (%) 0.207 Behçet 1 (1.2) 4 (3.3) Birdshot 8 (10.0) 19 (15.8) chorioretinitis b 16 (20.0) 18 (15.0) unknown 35 (43.8) 43 (35.8) HLA-B27 5 (6.2) 9 (7.5) MS 0 (0.0) 7 (5.8) Sarcoidosis 14 (17.5) 16 (13.3) VKH 1 (1.2) 4 (3.3) Oral prednisone, c N (%) 34 (42.5) 41 (34.2) 0.297 DMARD, c N (%) 20 (25.0) 74 (61.7) <0.001 Biologics, c,d N (%) 1 (1.2) 8 (6.7) 0.144 Table 1. Patient characteristics. a) At day of electroretinogram measurement. b) Includes patients with chorioiditis/chorioretinits of unknown cause, multiple evanescent white dot syndrome (MEWDS), acute multifocal placoid pigment epitheliopathy (AMPPE) and presumed ocular histoplasmosis syndrome (POHS). c) Treatment at time of ERG. d) adalimumab or infliximab. Abbreviations: IQR = interquartile range, HLA = human leukocyte antigen, MS = multiple sclerosis, VKH=Vogt–Koyanagi–Harada disease, DMARD=Disease-modifying anti-rheumatic drugs (i.e. methotrexate, azathioprine, mycophenolate mofetil, mycophenolate sodium, cyclosporine, cyclophosphamide).